ADDITION OF ZOLEDRONIC ACID (ZOL) TO ADJUVANT ENDOCRINE THERAPY IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (HREBC): MULTIVARIATE ANALYSES OF THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP 12 (ABCSG-12) TRIAL
- M Gnant (Autor*in)
- B Mlineritsch (Autor*in)
- Walter Schippinger (Autor*in)
- Gero Luschin-Ebengreuth (Autor*in)
- S Poestlberger (Autor*in)
- C Menzel (Autor*in)
- R Jakesz (Autor*in)
- E Kubista (Autor*in)
- C Marth (Autor*in)
- R Greil (Autor*in)
Aktivität: Vortrag oder Poster › Poster